Indus Pharma (Pvt.) Ltd.

indus-pharma.com

INDUS PHARMA was founded by the visionary founder Mr. Saeed Ismail in 1969. Since then, keeping in view the need of injectable, contrary to the prevailing trends of oral preparation, Indus Pharma continually evolved to keep pace with the needs and expectations of the healthcare professionals through developing innovative and better therapeutic products to prevent and treat diseases and improve health and well-being of the people.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

EVEREST MEDICINES APPOINTS ROGERS YONGQING LUO AS CHIEF EXECUTIVE OFFICER TO LEAD NEXT STAGE OF COMPANY GROWTH

Everest Medicines | September 19, 2022

news image

Everest Medicines a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced that it has appointed Rogers Yongqing Luo as Chief Executive Officer of the Company, effective immediately. Mr. Luo will also serve as an Executive Director on Everest's Board of Directors. Mr. Luo brings to Everest more than 25 years of experience in the healthcare industry with an ext...

Read More

COVECTRA ANNOUNCES VRS FOR PHARMACEUTICAL MANUFACTURERS TO ENHANCE DRUG SUPPLY CHAIN SECURITY

Covectra | June 22, 2020

news image

Covectra, a leader in track and trace solutions, today announced the Covectra Verification Router Service (VRS), a complete API solution enabling pharmaceutical brands to validate the status of a returned product to ascertain its resell ability and ensure regulatory compliance with the upcoming Drug Supply Chain and Security Act (DSCSA) saleable returns requirement. In November 2020, the FDA enforcement will begin as pharmaceutical distributors of regulated medicines will need to ...

Read More

Business Insights

ASYMCHEM AND LANOVA MEDICINES ENTER INTO PARTNERSHIP AGREEMENT, EXPANDING BIOLOGICAL CAPABILITIES

Asymchem | September 17, 2021

news image

Asymchem today announced a strategic partnership agreement to provide LaNova Medicines with one-stop services such as small molecule drugs, ADC project CMCs, R&D, production and IND China-US declaration. The collaboration between Asymchem and LaNova will include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives. This partnership will take full advantage of Asymchem's recently co...

Read More

Business Insights

LIGAND PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Ligand Pharmaceuticals | August 02, 2022

news image

Ligand Pharmaceuticals Incorporated announced that effective August 1, 2022, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 90,073 shares of its common stock, 5,000 restricted stock units and 4,000 performance stock units the target level to six non-executive employees. The options were granted on August 1, 2022, and the grant date for the RSUs and the PSUs will be the date on which Ligand files a Form S-8 Registration Statem...

Read More
news image

Business Insights

EVEREST MEDICINES APPOINTS ROGERS YONGQING LUO AS CHIEF EXECUTIVE OFFICER TO LEAD NEXT STAGE OF COMPANY GROWTH

Everest Medicines | September 19, 2022

Everest Medicines a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced that it has appointed Rogers Yongqing Luo as Chief Executive Officer of the Company, effective immediately. Mr. Luo will also serve as an Executive Director on Everest's Board of Directors. Mr. Luo brings to Everest more than 25 years of experience in the healthcare industry with an ext...

Read More
news image

COVECTRA ANNOUNCES VRS FOR PHARMACEUTICAL MANUFACTURERS TO ENHANCE DRUG SUPPLY CHAIN SECURITY

Covectra | June 22, 2020

Covectra, a leader in track and trace solutions, today announced the Covectra Verification Router Service (VRS), a complete API solution enabling pharmaceutical brands to validate the status of a returned product to ascertain its resell ability and ensure regulatory compliance with the upcoming Drug Supply Chain and Security Act (DSCSA) saleable returns requirement. In November 2020, the FDA enforcement will begin as pharmaceutical distributors of regulated medicines will need to ...

Read More
news image

Business Insights

ASYMCHEM AND LANOVA MEDICINES ENTER INTO PARTNERSHIP AGREEMENT, EXPANDING BIOLOGICAL CAPABILITIES

Asymchem | September 17, 2021

Asymchem today announced a strategic partnership agreement to provide LaNova Medicines with one-stop services such as small molecule drugs, ADC project CMCs, R&D, production and IND China-US declaration. The collaboration between Asymchem and LaNova will include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives. This partnership will take full advantage of Asymchem's recently co...

Read More
news image

Business Insights

LIGAND PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Ligand Pharmaceuticals | August 02, 2022

Ligand Pharmaceuticals Incorporated announced that effective August 1, 2022, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 90,073 shares of its common stock, 5,000 restricted stock units and 4,000 performance stock units the target level to six non-executive employees. The options were granted on August 1, 2022, and the grant date for the RSUs and the PSUs will be the date on which Ligand files a Form S-8 Registration Statem...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us